Cold pain therapy is a therapeutic application of cold, used in the treatment of acute soft tissue injuries and to reduce the pain in post-operative condition in orthopedic surgeries, treatment of benign and malignant lesions, and in pain management. Cryotherapy can be applied topically (on the skin surface), surgically or percutaneously. This can also be used to treat various skin conditions such as oral mucositis and tumors in the liver, kidney, bones, breasts and lungs, skin tumors, skin tags, pre-cancerous skin moles, and injuries.
Cryosurgery procedure involves use of extreme cold, produced with help of liquid nitrogen (or argon gas) to destroy abnormal tissues. According to the National Cancer Institute (NCI), cryosurgery is used for treatment of several types of cancers and some non-cancerous conditions. It is reported to be effective for treatment in early stage skin cancer, retinoblastoma, actinic keratosis, and cervical intraepithelial neoplasia. According to a study published in Journal of the National Cancer Institute, in October 2017, it was observed that cryotherapy was effective in controlling the side effects of chemotherapy induced peripheral neuropathy.
According to the U.S. Food & Drug Administration (FDA), cryotherapy is 'super cooling' of the body tissues for therapeutic purposes. Moreover, cryotherapy involves use of products such as ice packs on a certain portion of the body such as lower back. Whole Body Cryotherapy (WBC) involves exposing the body to liquid nitrogen vapors to reach ultra-low temperature ranging from -200 to -300 degrees Fahrenheit. WBC treatment is provided in relatively confined spaces or chamber for two to four minutes. However, U.S. FDA does not have sufficient evidence to recommend use of WBC to treat disease or conditions such as Alzheimer’s disease, rheumatoid arthritis, stress, multiple sclerosis, anxiety or chronic pain. Use of WBC has various risks such as burns, frostbite, and eye injury from extremely low temperature.
Increasing prevalence of skin, prostate, retinoblastoma, cervical cancer, and others and increasing rate of accidental and sport injuries are the major driving factors affecting growth of the cold pain therapy market. For instance, according to the Centers for Disease Control and Prevention (CDC), 12,578 women in the U.S. were diagnosed with cervical cancer while 4,115 women in the U.S. died from cervical cancer in 2014. In addition, according to the Cancer Research UK, 3,224 new cases of cervical cancer were reported in 2014, in the U.K., alone.
Moreover, increasing workplace related injuries and sport injuries is expected to boost growth of the cold pain therapy market. For instance, according to the Health and Safety Executive (HSE), 0.6 million non-fatal injuries at workplace were accounted in 2016. Moreover, new cases of work-related illness in the U.K. accounted for loses of US$ 12.4 billion in 2016. Furthermore, according to the U.S. Bureau of Labor Statistics 2016, around 2.9 million non-fatal workplace injuries and illness were reported by private industry employees in 2016.
Get PDF Brochure Of This Research Report @ :
https://www.coherentmarketinsights.com/insight/request-pdf/1162
Cold Pain Therapy Market Taxonomy:
On the basis of product, cold pain therapy market segmented into:
OTC-based products
Pharmaceuticals
Gels, ointment and creams
Patches
Spray and foams
Roll-ons
Medical devices
Cold packs
Cooling pads, wraps and pads
Prescription-based products
Motorized cryotherapy devices
Non-motorized cryotherapy devices
On the basis of therapy type, cold pain therapy market segmented into:
Cryosurgery
Icepack therapy
Chamber therapy
On the basis of device type, cold pain therapy market segmented into:
Spray cryogun
Dipstick applicator
Cryoprobe
Other devices
On the basis of application, cold pain therapy market segmented into:
Dermatology
Oncology
Musculoskeletal disorder
Pain management
Sport medicine
Physical therapy
Ophthalmology
Post-operative
Post-trauma
On the basis of distribution channel, cold pain therapy market segmented into:
Online pharmacies
Retail pharmacies
Hospital pharmacies
Recent developments in the cold pain therapy market
In July 2017, CSA Medical, Inc. received FDA clearance to expand truFreeze catheter offering to include Rapid AV Spray Kit. truFreeze system is used in cryosurgical procedures for application in gynecology, dermatology, general surgery, and in the removal of malignant lesions. Moreover, the addition of rapid AV Spray kit with truFreeze catheter is expected to reduce the surgical time thereby, reducing overall patient treatment time.
In January 2017, PENTAX Medical — a company engaged in manufacturing, development and R&D activities in endoscopic product and services — acquired the C2 Therapeutics. C2 Therapeutics manufactures C2 CryoBalloon Ablation System for endoscopic ablation of tissue. Moreover, the acquisition enabled PENTAX Medial to strengthen its therapeutic endoscopy products and service portfolio.
Request Sample Copy of Research Report @ :
https://www.coherentmarketinsights.com/insight/request-sample/1162
Key players in the cold pain therapy market:
Some of the key players in the cold pain therapy market are CryoConcepts LP, Metrum Cryoflex, Brymill Cryogenic Systems, Mectronic Mediccale S.r.l., Sanarus, Wallach Surgical Devices, Zimmer MedizinSystems, CooperSurgical Inc., CSA Medical, Inc., Cortex Technology, Erbe Elektromedizin, GmbH, Special Medical Technology Co., Ltd, Medtronic plc, Galil Medical, Inc., and PHYSIOMED AG
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]
(Albany, US) DelveInsight has launched a new report on Oral Mucositis Market Insights, Epidemiology and Market Forecast-2030DelveInsight’s “Oral Mucositis (OM) - Market Insights, Epidemiology and Market Forecast - 2030” report provides an overview of the disease and market size of Oral Mucositis for the 7MM major pharmaceutical markets, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
This report covers the various treatment practices, and Oral Mucositis forecasted epidemiology from 2020 to 2030, segmented by the 7 major markets.Some of the key facts of the Report:In 2017, US had the maximum number of incident cases of the total incident cases followed by Japan.Grade 3 or 4 Oral Mucositis occurs in around 85% of patients receiving high-dose radiotherapy.In 2017, the incident population of Oral Mucositis in the United States was 1,956,351.
)Oral Mucositis market report provides insights on the current and emerging therapies.
Oral Mucositis market report offers a global historical and forecasted market covering drug outreach in 7 MM.Oral Mucositis market report provides an edge that will help in developing business strategies by understanding trends shaping and driving the Malignant Mesothelioma market.Request for Sample Pages : https://www.delveinsight.com/sample-request/oral-mucositis-om-market“According to Delveinsight, females appear to be more likely than males to develop Oral mucositis.”View Report: https://www.delveinsight.com/report-store/oral-mucositis-om-marketOral Mucositis (OM) is the most common, debilitating complication of cancer chemotherapy and radiotherapy.
It is characterized by inflammation and ulceration in the oral cavity caused by the chemotherapeutic drug substances and radiotherapy used in cancer treatment.
The early symptoms include erythema and light discoloration of the mucosa.
COVID-19 Impact Analysis on Chemotherapy-Induced Oral Mucositis Market report published by Value Market Research provides a detailed market analysis comprising market size, share, value, growth and trends for the period 2020-2027.
Moreover, this market report also covers regional and country markets in detail.The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide.
The major players in the chemotherapy-induced oral mucositis market include Izun Pharmaceuticals, Aurora Bioscience, Camurus AB, Prothex Inc., Swedish Orphan Biovitrum AB, Soleva Pharma, Access Pharmaceutical Inc., NeoMedLight, INNOVATION Pharma, Monopar TherapeuticsAccess Pharmaceutical Inc., and Swedish Orphan Biovitrum AB.
This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.Get more information on "Global Chemotherapy-Induced Oral Mucositis Market Research Report" by requesting FREE Sample Copy at https://www.valuemarketresearch.com/contact/chemotherapy-induced-oral-mucositis-market/download-sampleMarket DynamicsThe increase in usage of chemotherapeutic agents due to the increasing incidence of cancers is the major factor driving the chemotherapy-induced oral mucositis market.
The rise in the number of patients receiving chemotherapy each year leads to a high need for the treatment of oral mucositis.
The increased elderly population, as they are more susceptible to cancer, is leading to high demand for the treatment of chemotherapy-induced oral mucositis.
